Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17133348 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | December 2020 | August 2022 | Allow | 19 | 1 | 0 | Yes | No |
| 17127979 | USE OF UAP INHIBITORS TO INHIBIT FLUX THROUGH THE HEXOSAMINE BIOSYNTHETIC PATHWAY | December 2020 | July 2023 | Allow | 31 | 2 | 0 | No | Yes |
| 17126007 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | December 2020 | August 2022 | Allow | 20 | 1 | 0 | No | No |
| 17252842 | DOT1L DEGRADERS AND USES THEREOF | December 2020 | December 2022 | Allow | 24 | 2 | 0 | No | No |
| 17251649 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | December 2020 | August 2023 | Allow | 32 | 0 | 0 | No | No |
| 17118314 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | December 2020 | June 2022 | Abandon | 18 | 1 | 0 | No | No |
| 16960271 | ACIDIC DYSTROGLYCAN OLIGOSACCHARIDE COMPOUND AND METHOD FOR MAKING SAME | December 2020 | August 2023 | Allow | 37 | 2 | 0 | No | No |
| 17116039 | D-ALLOSE CRYSTAL AND PRODUCTION METHOD THEREOF | December 2020 | March 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17116706 | OLIGOSACCHARIDE ANALYTICAL STANDARDS | December 2020 | May 2023 | Allow | 30 | 1 | 1 | No | No |
| 16973454 | TREATMENT OF POULTRY OR PIGS FOR REDUCING THE FEED CONVERSION RATIO OR INCREASING THEIR BODYWEIGHT GAIN | December 2020 | September 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17114721 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | December 2020 | June 2022 | Abandon | 18 | 1 | 0 | No | No |
| 17114177 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | December 2020 | July 2023 | Allow | 31 | 1 | 0 | No | No |
| 17109024 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | December 2020 | February 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17059097 | 3-OXAZOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | November 2020 | February 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17058845 | Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides | November 2020 | November 2023 | Allow | 36 | 1 | 0 | No | No |
| 17094037 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | November 2020 | October 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 17094045 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | November 2020 | June 2022 | Abandon | 19 | 1 | 0 | No | No |
| 17054124 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | November 2020 | January 2022 | Allow | 15 | 2 | 0 | No | No |
| 17070287 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | October 2020 | November 2021 | Allow | 13 | 0 | 0 | No | No |
| 17069184 | ANALOGUES OF ETOPOSIDE FOR THE TREATMENT OF TUMOURS | October 2020 | September 2023 | Allow | 35 | 2 | 0 | No | Yes |
| 17063545 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | October 2020 | March 2022 | Allow | 17 | 1 | 0 | No | No |
| 17044960 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | October 2020 | September 2022 | Allow | 24 | 0 | 1 | No | No |
| 17061409 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | October 2020 | May 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17060440 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | October 2020 | July 2023 | Allow | 34 | 1 | 0 | No | No |
| 16948659 | SOLID-STATE FORMS OF REGADENOSON, THEIR USE AND PREPARATION | September 2020 | August 2022 | Allow | 23 | 1 | 0 | No | No |
| 17028724 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | September 2020 | April 2022 | Abandon | 19 | 1 | 0 | No | No |
| 16981511 | PUROMYCIN-BASED PROBES AND METHODS OF USE THEREOF | September 2020 | April 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17018713 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | September 2020 | March 2022 | Allow | 18 | 1 | 0 | No | No |
| 16978093 | SUBSTITUTED PYRIDOPYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USES | September 2020 | January 2022 | Allow | 16 | 1 | 0 | Yes | No |
| 17010338 | FORMULATION COMPRISING A GEMCITABINE-PRODRUG | September 2020 | March 2021 | Allow | 12 | 1 | 0 | Yes | No |
| 17005110 | TRITERPENE SAPONIN ANALOGUES | August 2020 | March 2023 | Abandon | 30 | 2 | 0 | No | Yes |
| 17004067 | Method for Preparation of Derivatives of Gram-Positive Bacteria Surface Capsular Polysaccharide | August 2020 | October 2022 | Allow | 25 | 1 | 1 | No | No |
| 16975732 | MEDICAL USE | August 2020 | January 2022 | Allow | 17 | 1 | 0 | Yes | No |
| 16995237 | E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | August 2020 | January 2022 | Allow | 17 | 1 | 0 | No | No |
| 16987225 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | August 2020 | June 2022 | Allow | 22 | 1 | 0 | No | No |
| 16967584 | THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASE AND APPLICATION THEREOF | August 2020 | August 2022 | Allow | 25 | 2 | 0 | No | No |
| 16967306 | CELL LABELING AGENT AND CELL LABELING KIT | August 2020 | March 2024 | Allow | 43 | 1 | 0 | No | No |
| 16983552 | ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER | August 2020 | May 2022 | Allow | 22 | 2 | 0 | No | No |
| 16983310 | MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING | August 2020 | July 2022 | Allow | 23 | 2 | 0 | No | No |
| 16965747 | NICOTINAMIDE RIBOSIDE ANALOGS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | July 2020 | October 2021 | Allow | 14 | 1 | 0 | No | No |
| 16937246 | WATER SOLUBLE NITRIC OXIDE-RELEASING POLYGLUCOSAMINES AND USES THEREOF | July 2020 | September 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16936900 | ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME | July 2020 | January 2022 | Allow | 17 | 1 | 0 | No | No |
| 16963900 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF | July 2020 | January 2023 | Allow | 30 | 4 | 0 | Yes | No |
| 16963083 | THIAZOLE-5-CARBOXYLIC ACID DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | July 2020 | May 2022 | Allow | 22 | 2 | 0 | No | No |
| 16925977 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | July 2020 | July 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16924239 | Six-membered Ring-Containing Nucleoside Compound and Preparation Method Thereof | July 2020 | January 2021 | Allow | 6 | 1 | 0 | No | No |
| 16960996 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | July 2020 | March 2021 | Allow | 8 | 1 | 0 | No | No |
| 16960488 | GLUCOPYRANOSYL DERIVATIVE AND USE THEREOF | July 2020 | May 2021 | Allow | 11 | 1 | 0 | No | No |
| 16918898 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | July 2020 | November 2020 | Allow | 4 | 1 | 0 | No | No |
| 16918914 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | July 2020 | November 2020 | Allow | 4 | 1 | 0 | No | No |
| 16918918 | NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS | July 2020 | November 2020 | Allow | 4 | 1 | 0 | No | No |
| 15733302 | NOVEL THIOPHOSPHORAMIDITES | June 2020 | September 2022 | Allow | 27 | 1 | 0 | No | No |
| 16900154 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | June 2020 | September 2023 | Allow | 39 | 2 | 1 | No | No |
| 16900397 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | June 2020 | November 2020 | Allow | 5 | 1 | 0 | No | No |
| 16771741 | GLYCOSIDIC DERIVATIVES OF TREPROSTINIL | June 2020 | June 2022 | Allow | 24 | 1 | 0 | No | No |
| 16897690 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | June 2020 | February 2024 | Abandon | 44 | 3 | 1 | No | No |
| 16769793 | NOVEL SPIROBICYCLIC ANALOGUES | June 2020 | March 2021 | Allow | 9 | 1 | 0 | No | No |
| 16891824 | NICOTINAMIDE RIBOSIDE COMPOSITIONS FOR TOPICAL USE IN TREATING SKIN CONDITIONS | June 2020 | April 2021 | Allow | 11 | 1 | 0 | No | No |
| 16881419 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | May 2020 | August 2021 | Allow | 14 | 1 | 0 | No | No |
| 16766610 | NOVEL INHIBITORS OF THE SHIKIMATE PATHWAY | May 2020 | August 2022 | Allow | 26 | 1 | 1 | No | No |
| 16876843 | A PROCESS FOR THE MANUFACTURE OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | May 2020 | February 2021 | Allow | 9 | 0 | 0 | No | No |
| 16872802 | CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | May 2020 | February 2021 | Allow | 9 | 1 | 0 | No | No |
| 16865527 | GEMCITABINE PRODRUGS | May 2020 | November 2022 | Allow | 31 | 1 | 0 | No | No |
| 16760781 | NUCLEOSIDE DERIVATIVE AND USE THEREOF | April 2020 | May 2023 | Allow | 37 | 1 | 1 | No | No |
| 16760700 | GSK-3� INHIBITORS AND USE THEREOF IN METHODS OF TREATMEN | April 2020 | November 2021 | Allow | 18 | 2 | 0 | No | No |
| 16863566 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | April 2020 | December 2020 | Allow | 8 | 1 | 0 | No | No |
| 16859007 | Monosaccharide Amine and 3-Nitro-2-Phenyl-2H-Chromene Based Inhibitors of Glucose Kinases | April 2020 | March 2021 | Allow | 11 | 1 | 0 | No | No |
| 16853393 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | April 2020 | October 2021 | Allow | 18 | 1 | 1 | No | No |
| 16848268 | CARBOHYDRATE LIGANDS THAT BIND TO IGM ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN | April 2020 | August 2021 | Allow | 17 | 1 | 0 | No | No |
| 16847737 | SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE | April 2020 | May 2021 | Allow | 13 | 1 | 0 | No | No |
| 16755779 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | April 2020 | April 2021 | Allow | 12 | 2 | 0 | No | No |
| 16847552 | PROCESS FOR MAKING 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2, 7-DIONE COMPOUNDS USEFUL FOR THE TREATMENT OF VIRUS INFECTION | April 2020 | March 2021 | Allow | 60 | 1 | 0 | No | No |
| 16755580 | NOVEL AMPHIPHILIC COMPOUND HAVING DENDRONIC HYDROPHOBIC GROUP AND APPLICATION THEREOF | April 2020 | August 2022 | Allow | 28 | 0 | 0 | No | No |
| 16754301 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | April 2020 | January 2023 | Allow | 33 | 2 | 0 | No | No |
| 16753998 | SUGAR-LINKED AMINO ACIDS FOR SOLID-PHASE PEPTIDE SYNTHESIS | April 2020 | March 2022 | Abandon | 23 | 1 | 1 | No | No |
| 16612289 | PHOSPHORYLATED HEPTOSE COMPOUNDS: PROCESS FOR THEIR PREPARATION AND USE | March 2020 | February 2023 | Allow | 39 | 1 | 1 | No | No |
| 16649892 | TRITERPENE SAPONIN ANALOGUES | March 2020 | December 2021 | Allow | 20 | 1 | 0 | No | No |
| 16827220 | TRITERPENE SAPONIN ANALOGUES | March 2020 | August 2020 | Allow | 5 | 1 | 0 | No | No |
| 16648405 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | March 2020 | February 2021 | Allow | 11 | 0 | 0 | Yes | No |
| 16647592 | FLOXURIDINE SYNTHESIS | March 2020 | March 2022 | Allow | 24 | 1 | 0 | No | No |
| 16647236 | MODIFIED NUCLEOSIDE PHOSPHORAMIDITES | March 2020 | July 2021 | Allow | 16 | 2 | 0 | No | No |
| 16643393 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | February 2020 | December 2022 | Allow | 33 | 1 | 0 | No | No |
| 16804153 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | February 2020 | August 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16642879 | AMINOGLYCOSIDES AND USES THEREOF | February 2020 | February 2022 | Allow | 24 | 1 | 0 | No | No |
| 16642424 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | February 2020 | October 2020 | Allow | 8 | 1 | 0 | No | No |
| 16642189 | KAEMPFEROL ANALOG-CONTAINING COMPOSITION | February 2020 | June 2021 | Abandon | 16 | 1 | 0 | No | No |
| 16800694 | DERIVATIVES OF AMPHOTERICIN B | February 2020 | September 2020 | Allow | 7 | 1 | 0 | No | No |
| 16641679 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | February 2020 | September 2020 | Allow | 6 | 1 | 0 | No | No |
| 16641209 | SPIROTHIETANE NUCLEOSIDES | February 2020 | October 2021 | Allow | 20 | 1 | 0 | No | No |
| 16640845 | BROAD SPECTRUM VIRAL INHIBITOR | February 2020 | November 2021 | Allow | 21 | 3 | 0 | No | No |
| 16796085 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | February 2020 | July 2021 | Abandon | 17 | 1 | 0 | No | No |
| 16791079 | CARBOHYDRATE DERIVATIVES USED FOR SURFACE MODIFICATION OF IMMUNE CELLS, USE THEREOF AND METHOD THEREOF | February 2020 | March 2021 | Allow | 13 | 1 | 0 | No | No |
| 16787402 | PROCESSES FOR PREPARING SORBOSE FROM GLUCOSE | February 2020 | December 2021 | Allow | 22 | 0 | 0 | No | No |
| 16637647 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | February 2020 | May 2021 | Allow | 15 | 0 | 0 | Yes | No |
| 16637477 | LINCOSAMIDE ANTIBIOTICS AND USES THEREOF | February 2020 | September 2022 | Allow | 32 | 3 | 0 | No | No |
| 16781757 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | February 2020 | March 2021 | Allow | 13 | 2 | 0 | No | No |
| 16778281 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | January 2020 | October 2020 | Allow | 8 | 2 | 0 | No | No |
| 16773406 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | January 2020 | May 2021 | Allow | 15 | 1 | 0 | No | No |
| 16749500 | RNA-EDITING OLIGONUCLEOTIDES AND USES THEREOF | January 2020 | August 2022 | Allow | 30 | 2 | 1 | No | No |
| 16631653 | PHOTORESPONSIVE NUCLEOTIDE ANALOG CAPABLE OF PHOTOCROSSLINKING IN VISIBLE LIGHT REGION | January 2020 | July 2021 | Allow | 18 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCINTOSH III, TRAVISS C.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCINTOSH III, TRAVISS C works in Art Unit 1623 and has examined 769 patent applications in our dataset. With an allowance rate of 59.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 26 months.
Examiner MCINTOSH III, TRAVISS C's allowance rate of 59.4% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCINTOSH III, TRAVISS C receive 1.42 office actions before reaching final disposition. This places the examiner in the 20% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MCINTOSH III, TRAVISS C is 26 months. This places the examiner in the 73% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -5.6% benefit to allowance rate for applications examined by MCINTOSH III, TRAVISS C. This interview benefit is in the 6% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 37.1% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 54.5% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 92.9% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.0% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.